Notice of Preliminary Results date: 28 April 2016

RNS Number : 6088Q
Oxford Biomedica PLC
01 March 2016
 

 

 

 

 

 

 

Oxford BioMedica: Notice of Preliminary Results 

Results date: 28 April 2016

 

 

Oxford, UK - 29 February 2016: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene and cell therapy company, will be announcing its preliminary results for the twelve months ended 31 December 2015 on Thursday 28 April 2016.

 

An analyst briefing will be held at 11am BST on 28 April 2016 at the offices of Consilium Strategic Communications: 41 Lothbury, London, EC2R 7HG. A conference call will be hosted simultaneously and dial-in details will be provided on the day of the announcement. An audio replay will be made available shortly after the presentation on the Group's website: www.oxfordbiomedica.co.uk.

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/ Matthew Neal/ Chris Welsh/ Laura Thornton

Consilium Strategic Communications

 

 

Tel: +44 (0)20 3709 5700

 

 

Notes to editors

 

 

About Oxford BioMedica®

 

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NOREANDFEDKKEEF